MK-677 vs Retatrutide for appetite
Short answer: For appetite, more users report improvement with Retatrutide — 73% of 86 reports, versus 66% of 228 for MK-677.
MK-677 has 0 meta-analyses and 15 randomized trials on PubMed; Retatrutide has 22 and 6.
Based on 978 reports about MK-677 and 460 about Retatrutide. Not medical advice.
| MK-677 Substance | Retatrutide Peptide | |
|---|---|---|
| Users say it helped | 39%helped479 reports · high confidence | 76%helped327 reports · high confidence |
| Verdict | Mixed | Mostly positive |
| Research | BResearch: Moderate | BResearch: Moderate |
| Meta-analyses / RCTs | 0 / 15 | 22 / 6 |
| Mainly used for | ||
| Appetite % reporting improvement | 66% (228) | 73% (86) |
| Weight loss % reporting improvement | 53% (55) | 92% (228) |
| Sleep % reporting improvement | 79% (170) | 31% (26) |
| Energy % reporting improvement | 37% (62) | 69% (75) |
| Performance % reporting improvement | 90% (87) | 82% (33) |
| Common side effects | water retention, fatigue, stomach issues, hunger | nausea, fatigue, stomach issues, insomnia |
| Typical dose reported | 12.5 mg / before dinner | Not listed |
“From my own experience (also have suffered from poor sleep), i experienced a noticeable increase in sleep quality even with a low dose.”
This systematic review identifies the state and mechanism of action of emerging pharmacotherapies undergoing or having completed phase 2 and phase 3 clinical trials. The information provided herein furthers the understanding of obesity management, implying direct clinical implications and stimulating research initiatives.
Pharmacol Rev, 2025 ↗“Drastically reduced appetite: At 5mg, I experienced near-total suppression of hunger and cravings. Steady, effortless fat loss: I didn't have to track macros obsessively or do extreme cardio.”
Related comparisons
Percentages come from first-hand user reports and are not clinical outcomes. Talk to a doctor before starting, stopping or combining anything. How we rate